Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Simulations Plus sells software and consulting services that help drug companies simulate how medicines will behave in the body before testing them on real people.
Simulations Plus makes software that lets drug researchers test medicines inside a computer before testing them on people. If you want to know how a pill gets absorbed, how it moves through the bloodstream, or whether it might interfere with the liver, you can build a model of the human body in their software and run the experiment digitally. That is much faster than a lab, and it helps companies kill bad drug candidates early, before they spend fortunes on trials.
The company sells two main things. The first is software licenses β scientists at big pharmaceutical companies and smaller biotechs pay to use its modeling tools, and they pay again each year to keep using them. The second is consulting: when a drugmaker has a tricky question about dosing, safety, or how a new medicine might interact with other drugs, Simulations Plus employs its own scientists to run the simulations and hand over an answer. Regulators, including the U.S. Food and Drug Administration, have accepted these kinds of computer models as evidence in drug applications, which makes the software more valuable to customers who need to satisfy regulators without a giant trial. The business rests on a simple bet: better math means fewer failed drugs. A dose that looks fine in animals can be dangerous in humans, so smart simulation saves lives and money. But the company is small, and it competes with bigger analytics and software vendors plus in-house teams at large drugmakers. Its customers are loyal because the models are validated and regulatory experience matters, and that is the real moat β once a drugmaker's workflow and regulatory filings depend on a particular simulation platform, switching is painful.
Simulations Plus has been around since the 1990s, founded by scientists with a background in modeling. It grew through a mix of steady software subscriptions and acquisitions that added new modeling specialties. Its shares used to trade on NASDAQ under the ticker SLP, but today's sources say those shares no longer trade β the company has moved into private ownership, so there is no current public stock price. That shift does not change what the business does: it still sells simulation software and consulting to pharmaceutical researchers, and its fortunes still rise and fall with how much the drug industry values computer models over trial-and-error.
Saved answer Β· last researched 16 Nov 2026